Enzymotec (ENZY) Misses Q2 EPS by 4c; Trims FY16 Outlook

August 9, 2016 7:34 AM EDT
Get Alerts ENZY Hot Sheet
Trade ENZY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Enzymotec (NASDAQ: ENZY) reported Q2 EPS of $0.04, $0.04 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $15 million versus the consensus estimate of $14.9 million.


Enzymotec sees FY2016 EPS of $0.25-$0.30, versus the consensus of $0.29. Enzymotec sees FY2016 revenue of $52-56 million, versus the consensus of $60.0 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance, Hot Guidance

Related Entities


Add Your Comment